Jiřı́ Mayer

28.0k total citations · 3 hit papers
421 papers, 8.7k citations indexed

About

Jiřı́ Mayer is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Jiřı́ Mayer has authored 421 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Genetics, 177 papers in Hematology and 125 papers in Pathology and Forensic Medicine. Recurrent topics in Jiřı́ Mayer's work include Chronic Lymphocytic Leukemia Research (169 papers), Lymphoma Diagnosis and Treatment (113 papers) and Chronic Myeloid Leukemia Treatments (86 papers). Jiřı́ Mayer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (169 papers), Lymphoma Diagnosis and Treatment (113 papers) and Chronic Myeloid Leukemia Treatments (86 papers). Jiřı́ Mayer collaborates with scholars based in Czechia, United States and Germany. Jiřı́ Mayer's co-authors include Šárka Pospı́šilová, Michael Doubek, Andreas Hochhaus, Michele Baccarani, Hagop M. Kantarjian, Jörge E. Cortes, Concepción Boqué, Charles Chuah, Neil P. Shah and Marek Mráz and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Jiřı́ Mayer

397 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

2010 1.1k citations Hagop M. Kantarjian, Neil P. Shah et al. profile →
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

2016 621 citations Jörge E. Cortes, Giuseppe Saglio et al. Journal of Clinical Oncology profile →
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

2018 237 citations Jiřı́ Mayer, Nichola Cooper et al. American Journal of Hematology profile →

Peers

Countries citing papers authored by Jiřı́ Mayer

Since Specialization

Citations

This map shows the geographic impact of Jiřı́ Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiřı́ Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiřı́ Mayer more than expected).

Fields of papers citing papers by Jiřı́ Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiřı́ Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiřı́ Mayer. The network helps show where Jiřı́ Mayer may publish in the future.

Co-authorship network of co-authors of Jiřı́ Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of Jiřı́ Mayer. A scholar is included among the top collaborators of Jiřı́ Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiřı́ Mayer. Jiřı́ Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Real‐World Data From a Molecular Tumor Board‐Assisted Cancer Care From a Single Center in The Czech Republic: Is Precision Oncology an Accessible Option, or a Privilege for a Minority of Patients? 2025 ·Cancer Medicine ·(unknown), Markéta Bednaříková, (unknown), Jitka Hausnerová, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Zdeněk Pavlovský, (unknown), (unknown), (unknown), Tomáš Rohan, Zdeněk Kala, (unknown), Jiřı́ Mayer, Adam Svobodník, (unknown)	1
2	Long-term treatment with rilzabrutinib in patients with immune thrombocytopenia 2024 ·Blood Advances ·David J. Kuter, Jiřı́ Mayer, (unknown), (unknown), Ross Baker, Zane Kaplan, Mamta Garg, Marek Trněný, Philip Choi, A.J. Gerard Jansen, Vickie McDonald, Robert Bird, Jaromír Gumulec, Milan Košťál, Terry Gernsheimer, Waleed Ghanima, Ahmed Daak, Nichola Cooper	11
3	Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study 2024 ·British Journal of Haematology ·Klaus Geißler, Zdeněk Kořı́stek, Teresa Bernal, Jan Novák, Gabriela Rodríguez‐Macías, Stephan Metzelder, Árpád Illés, Jiřı́ Mayer, Montserrat Arnán, Mary‐Margaret Keating, (unknown), Monia Lunghi, Nicola Stefano Fracchiolla, Uwe Platzbecker, Valeria Santini, Yuri Sano, Aram Oganesian, Harold Keer, Michael Lübbert	8
4	Management of pheochromocytomas and paragangliomas: Review of current diagnosis and treatment options 2023 ·Cancer Medicine ·(unknown), (unknown), Dana Sochorová, (unknown), (unknown), Zdeněk Kala, Jiřı́ Mayer, Radim Němeček, Jan Trna, Lumír Kunovský	10
5	Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials 2023 ·HemaSphere ·Jean‐Jacques Kiladjian, Alessandro M. Vannucchi, Aaron T. Gerds, Vikas Gupta, Srđan Verstovšek, Miklós Egyed, Uwe Platzbecker, Jiřı́ Mayer, Sebastian Grosicki, Árpád Illés, (unknown), Stephen T. Oh, Donal P. McLornan, Ilya Kirgner, Sung‐Soo Yoon, Claire Harrison, Barbara Klencke, Mei Huang, Jun Kawashima, Ruben A. Mesa	10
6	A phase 2 study of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B‐cell malignancies: waveLINE‐006 2023 ·Hematological Oncology ·Pier Luigi Zinzani, Jiřı́ Mayer, Ohad Benjamini, (unknown), Ingrid Glimelius, Don A. Stevens, Arvind Chaudhry, Ahmet Muzaffer Demir, (unknown), W. S. Kim, Fei Li, (unknown), Ana Marín‐Niebla, Muhıt Özcan, Ewa Paszkiewicz‐Kozik, Armando Santoro, Yi Ren, Uzor C. Ogbu, Patricia Marinello, Wojciech Jurczak	2
7	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene 2022 ·Epigenetics ·(unknown), Šárka Pavlová, Beatríz González, Jana Kotašková, Karla Plevová, Gabrijela Dumbović, Pavlína Janovská, Vojtěch Bystrý, (unknown), (unknown), (unknown), Yvona Brychtová, Michael Doubek, (unknown), Marek Borský, Jiřı́ Mayer, Vı́tězslav Bryja, Sergio Alonso, Šárka Pospı́šilová	3
8	Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options 2021 ·Blood ·Jitka Malčíková, Šárka Pavlová, (unknown), Lenka Radová, Karla Plevová, Jana Kotašková, Karol Pál, (unknown), (unknown), (unknown), (unknown), (unknown), Yvona Brychtová, (unknown), Boris Tichý, Nikola Tom, Jiřı́ Mayer, Michael Doubek, Šárka Pospı́šilová	24
9	Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial breakdown → 2016 ·Journal of Clinical Oncology ·Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian, Michele Baccarani, Jiřı́ Mayer, Concepción Boqué, Neil P. Shah, Charles Chuah, Luís Casanova, (unknown), George Manos, Andreas Hochhaus	621
10	IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY 2016 ·Haematologica ·Graeme Fraser, Paula Cramer, Fatih Demırkan, (unknown), Sebastian Grosicki, Ann Janssens, Jiřı́ Mayer, Marie‐Sarah Dilhuydy, Halyna Pylypenko, Javier Loscertales, André Goy, Abraham Avigdor, (unknown), Charles E. Phelps, Michelle Mahler, Mariya Salman, Angela Howes, Michael Hallek	4
11	Incorporation of humanized niche as a strategy for improvingleukemic engraftment in immunodeficient mice 2015 ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jiřı́ Mayer, Zdeněk Ráčil	2
12	Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911) 2013 ·Blood ·Peter Hillmen, Tadeusz Robak, Ann Janssens, (unknown), Sebastian Grosicki, Jiřı́ Mayer, Panagiotis Panagiotidis, Eva Kimby, Anna Schuh, Thomas E. Boyd, Marco Montillo, Astrid McKeown, Jodi Carey, Ira Gupta, Chai‐Ni Chang, Steen Lisby, Fritz Offner	58
13	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia 2011 ·Blood ·William G. Wierda, Thomas J. Kipps, Jan Dürig, Laimonas Griškevičius, Stephan Stilgenbauer, Jiřı́ Mayer, Lukáš Smolej, Georg Heß, (unknown), Francisco J. Hernandez‐Ilizaliturri, Swaminathan P. Iyer, M Gorczyca, (unknown), Geoffrey Chan, Ira Gupta, Tina Nielsen, Charlotte Russell	86
14	Monitoring of minimal residual disease in acute myeloidleukemia with frequent and rare patient-specific NPM1 mutations 2010 ·American Journal of Hematology ·Dana Dvořáková, Zdeněk Ráčil, (unknown), (unknown), (unknown), Martina Lengerová, Filip Rázga, Jiřı́ Mayer	4
15	New prognostic markers of chronic lymphocytic leukemia in theeveryday hematological practice. A multicenter analysis. 2009 ·Michael Doubek, (unknown), (unknown), Martin Brejcha, Zdeněk Pospı́šil, (unknown), Yvona Brychtová, Šárka Pospı́šilová, Petr Cetkovský, Marek Trněný, Jiřı́ Mayer	0
16	Circulating ofatumumab concentrations correlate with responseand progression-free survival in fludarabine-refractory chroniclymphocytic leukemia 2009 ·Haematologica ·(unknown), (unknown), (unknown), TJ Kipps, Jiřı́ Mayer	1
17	Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia 2007 ·Journal of Clinical Oncology ·Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jakšić, Anna Dmoszyńska, Jingyang Wu, Cynthia A. Sirard, Jiřı́ Mayer	408
18	Real-Time PCR Diagnostics Failure Caused by Nucleotide Variability within Exon 4 of the Human Cytomegalovirus Major Immediate-Early Gene 2007 ·Journal of Clinical Microbiology ·Martina Lengerová, Zdeněk Ráčil, (unknown), (unknown), (unknown), Dana Dvořáková, Jiří Vorlíček, Jiřı́ Mayer	13
19	Autologous transplantation of mononuclear bone marrow cells in patients with chronic myocardial infarction 2007 ·Cor et Vasa ·Jaroslav Meluzı́n, Stanislav Janoušek, Jiřı́ Mayer, Ladislav Groch, Jan Sitar, (unknown), Petr Kala, Roman Panovský, Milan Kamínek, Martin Klabusay, Zdeněk Kořı́stek, Ladislav Dušek	3
20	Bone Marrow Processing for Transplantation Using the COBE Spectra Cell Separator 1999 ·Journal of Hematotherapy & Stem Cell Research ·Zdeněk Kořı́stek, Jiřı́ Mayer	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact